Passer au contenu principal

Myocardite

Professionnels de la santé

Les articles de référence professionnelle sont conçus pour être utilisés par les professionnels de santé. Ils sont rédigés par des médecins britanniques et basés sur des preuves de recherche, des directives britanniques et européennes. Vous pouvez trouver le Myocarditearticle plus utile, ou l'un de nos autres articles de santé.

Continuez à lire ci-dessous

What is myocarditis?

Myocarditis is acute or chronic inflammation of the myocardium - and may present similarly to myocardial infarction. Myocardial destruction may lead to dilated cardiomyopathy.

The exact incidence of myocarditis is unknown. A primary diagnosis of myocarditis accounted for 0.04% (36.5 per 100,000) of all hospital admissions in England between 1998 and 2017, although this is likely to be an underestimate of the true burden of myocarditis.

Continuez à lire ci-dessous

This is very variable, from asymptomatic changes seen on ECG to fulminant myocarditis, which is characterised by a rapid progressive decline in cardiac function and a high mortality rate.2

  • Patients may be asymptomatic with ECG abnormalities.

  • Others may have severe heart failure and left ventricular dysfunction (LVD).

Patients commonly complain of:

  • Fatigue (>50% of patients).

  • Chest pain (35% of patients).

  • Fever (20% of patients).

  • Dyspnée.

  • Palpitations.

  • Tachycardia (may occur).

  • Heart sounds - soft S1 or S4 gallop rhythm.

  • Signs of heart failure.

Infection

  • Viral infection is the most common cause of acute myocarditis.3

  • Coxsackievirus is the most common viral cause in Europe and the USA; however, most viruses are potential agents, including adenovirus, parvovirus B19, enteroviruses, HIV, Epstein-Barr virus and hepatitis A and hepatitis C.4

  • Worldwide the most common bacterial cause is diphtheria.

  • There are also spirochetal, fungal, parasitic and rickettsial causes.

  • The protozoal Chagas' disease is a common entity worldwide.5

Immune-mediated

  • Sarcoïdose.

  • Systemic lupus erythematosus.

  • Scleroderma.

  • Chlamydophila pneumoniae (chlamydial pneumonia).

  • Churg-Strauss syndrome.

  • Maladie inflammatoire de l'intestin.

  • Giant cell myocarditis.

  • Diabète de type 1.

  • Kawasaki disease.

  • Myasthenia gravis.

  • Polymyositis.

  • Thyrotoxicosis.

  • Granulomatosis with polyangiitis.

  • Heart transplant rejection.

Drugs causing hypersensitivity reactions
Clozapine, acetazolamide, amitriptyline, cefaclor, colchicine, furosemide, isoniazid, lidocaine, methyldopa, penicillin, phenytoin, streptomycin, tetracycline, thiazides and tetanus toxoid.

Eosinophilic myocarditis is a rare form of myocardial inflammation with variable aetiology. In developed countries, the most common causes are hypersensitivity or allergic reactions, as well as various conditions leading to eosinophilia.6

Toxic myocarditis

  • Médicaments: ethanol, cytotoxic antibiotics (anthracyclines - eg, doxorubicin), amfetamines, cocaine, cyclophosphamide, fluorouracil, lithium, interleukin-2 and trastuzumab may exert a direct cytotoxic effect.

  • Intoxication aux métaux lourds: lead, copper, iron.

  • Autres: arsenic, insect stings and bites, phosphorus, carbon monoxide and inhalants.

Physical agents

  • Electric shock

  • Hyperpyrexia

  • Radiation/radiotherapy

Continuez à lire ci-dessous

  • ECG: changes may include ST-segment elevation/depression, T-wave inversion, atrial arrhythmias, transient atrioventricular (AV) block.

  • Blood tests: FBC (leukocytosis in 25%), U&E, creatine kinase (often elevated, as are other markers of myocardial cell damage, including troponin I and troponin T), ESR or CRP (elevated in 60%), LFT.

  • Radiographie thoracique :

    • Normal cardiac silhouette but pericarditis or overt clinical congestive heart failure is associated with cardiomegaly.

    • Vascular redistribution.

    • Interstitial and alveolar oedema.

    • Pleural effusion.

  • Viral or Chagas' serology may be helpful occasionally, as may autoantibodies (to screen for systemic autoimmune disease - eg, scleroderma).8

  • Endomyocardial biopsy (the gold standard test) is sometimes performed - but has only limited sensitivity and specificity.9

  • Cardiac MRI can differentiate transient and permanent tissue damage. Therefore, cardiac MRI is clinically useful to differentiate acute myocarditis from infarction.

Treat the underlying cause. Patients with signs of acute myocarditis (fever, WCC, flu-like illness and haemodynamic compromise) should be transferred to ITU, as ventricular support may become necessary. For an outline of appropriate supportive measures, see the separate Heart Failure Management article.

Patients may recover or progress to intractable heart failure (mechanical support devices may be needed, as precipitous cardiac decompensation can occur).

  • Treatment of acute myocarditis is still mainly supportive, except for giant cell myocarditis where steroids have been shown to improve survival.3

  • In patients with severe myocarditis and symptomatic hypotension, parenteral inotropes, including phosphodiesterase inhibitors (eg, milrinone) or adrenergic agonists (eg, dobutamine or dopamine) may be required.5

  • The use of anticoagulation is similar to that in patients with non-ischaemic dilated cardiomyopathy; anticoagulation is usually indicated for patients with concomitant atrial fibrillation or arterial or venous thromboembolism.5

  • Corticosteroids do not reduce mortality for people diagnosed with viral myocarditis and low left ventricular ejection fraction (LVEF). There is some evidence that corticosteroids may improve cardiac function but only from small, low-quality studies.10

  • There is currently insufficient evidence to support the routine use of intravenous immunoglobulin for presumed viral myocarditis in children or adults.11

After recovery from acute myocarditis, patients should be advised to limit activity for several months.5

The prognosis for patients with acute myocarditis is very variable and depends on clinical presentation, LVEF and pulmonary artery pressure.5

Lectures complémentaires et références

  • Law YM, Lal AK, Chen S, et al; Diagnosis and Management of Myocarditis in Children: A Scientific Statement From the American Heart Association. Circulation. 2021 Aug 10;144(6):e123-e135. doi: 10.1161/CIR.0000000000001001. Epub 2021 Jul 7.
  1. Ammirati E, Frigerio M, Adler ED, et al; Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail. 2020 Nov;13(11):e007405. doi: 10.1161/CIRCHEARTFAILURE.120.007405. Epub 2020 Nov 12.
  2. Hang W, Chen C, Seubert JM, et al; Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. Signal Transduct Target Ther. 2020 Dec 11;5(1):287. doi: 10.1038/s41392-020-00360-y.
  3. Shauer A, Gotsman I, Keren A, et al; Acute viral myocarditis: current concepts in diagnosis and treatment. Isr Med Assoc J. 2013 Mar;15(3):180-5.
  4. Dennert R, Crijns HJ, Heymans S; Acute viral myocarditis. Eur Heart J. 2008 Jul 9.
  5. Schultz JC, Hilliard AA, Cooper LT Jr, et al; Diagnosis and treatment of viral myocarditis. Mayo Clin Proc. 2009 Nov;84(11):1001-9. doi: 10.1016/S0025-6196(11)60670-8.
  6. Kuchynka P, Palecek T, Masek M, et al; Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis. Biomed Res Int. 2016;2016:2829583. doi: 10.1155/2016/2829583. Epub 2016 Jan 17.
  7. Ammirati E, Veronese G, Bottiroli M, et al; Update on acute myocarditis. Trends Cardiovasc Med. 2021 Aug;31(6):370-379. doi: 10.1016/j.tcm.2020.05.008. Epub 2020 Jun 1.
  8. Frishman WH, Zeidner J, Naseer N; Diagnosis and management of viral myocarditis. Curr Treat Options Cardiovasc Med. 2007 Dec;9(6):450-64.
  9. Greulich S, Ferreira VM, Dall'Armellina E, et al; Myocardial Inflammation - Are We There Yet? Curr Cardiovasc Imaging Rep. 2015;8(3):6.
  10. Chen HS, Wang W, Wu SN, et al; Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2013 Oct 18;10:CD004471. doi: 10.1002/14651858.CD004471.pub3.
  11. Robinson J, Hartling L, Vandermeer B, et al; Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2020 Aug 19;8:CD004370. doi: 10.1002/14651858.CD004370.pub4.

Continuez à lire ci-dessous

Historique de l'article

Les informations sur cette page sont rédigées et examinées par des cliniciens qualifiés.

flu eligibility checker

Demandez, partagez, connectez-vous.

Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets de santé.

symptom checker

Vous ne vous sentez pas bien ?

Évaluez vos symptômes en ligne gratuitement